SG
MGRX icon

StoneX Group’s Mangoceuticals MGRX Stock Holding History

StoneX Group’s Portfolio MGRX Stock Details MGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$5.78K Buy
+16,039
New +$7.68K ﹤0.01% 877
2024
Q4 		– Sell
-910
Closed -$3.22K – 899
2024
Q3 		$3.22K Buy
+910
New +$4.29K ﹤0.01% 357

Other funds holding MGRX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
ACA
Ackerman Capital Advisors Dallas, Texas $488M AUM 14.36% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

StoneX Group's MGRX Position: Q1 2026 in Review

StoneX Group opened a new position in Mangoceuticals (MGRX) in Q1 2026: 16,039 shares worth $5.78K. The stake represents ﹤0.01% of the portfolio and ranks #877 among its holdings. This is a return to the name: StoneX Group previously reported a position in MGRX as recently as Q3 2024.

StoneX Group first reported a position in MGRX in Q3 2024 and has held it in 2 quarters since. 18 funds tracked by Wall St. Rank hold MGRX as of Q1 2026.

  • StoneX Group held 16,039 shares of Mangoceuticals worth $5.78K as of Q1 2026.
  • Mangoceuticals was a new StoneX Group position in Q1 2026.
  • Mangoceuticals made up ﹤0.01% of StoneX Group's portfolio in Q1 2026, its #877 holding.
  • StoneX Group first reported a position in Mangoceuticals in Q3 2024 and has held it in 2 quarters since.
  • 18 funds tracked by Wall St. Rank held Mangoceuticals as of Q1 2026.

Based on StoneX Group's 13F filing for Q1 2026, filed 14 May 2026.